bThe Tigecycline Evaluation and Surveillance Trial (TEST) was designed to monitor susceptibility to commonly used antimicrobial agents among important pathogens. We report here on susceptibility among Gram-negative pathogens collected globally from pediatric patients between 2004 and 2012. Antimicrobial susceptibility was determined using guidelines published by the Clinical and Laboratory Standards Institute (CLSI). Most Enterobacteriaceae showed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to minocycline, and susceptibility rates were highest in North America, Europe, and Asia/Pacific Rim. Amikacin was the most active agent against Pseudomonas aeruginosa (90.4% susceptibility), with susceptibility rates being highest in North America. Extended-spectrum -lactamases (ESBLs) were reported for 11.0% of Escherichia coli isolates and 24.2% of Klebsiella pneumoniae isolates globally, with rates reaching as high as 25.7% in the Middle East and >43% in Africa and Latin America, respectively. Statistically significant (P < 0.01) differences in susceptibility rates were noted between pediatric age groups (1 to 5 years, 6 to 12 years, or 13 to 17 years of age), globally and in some regions, for all pathogens except Haemophilus influenzae. Significant (P < 0.01) differences were reported for all pathogens globally and in most regions, considerably more frequently, when pediatric and adult susceptibility results were compared. Amikacin, tigecycline, and the carbapenems were active in vitro against most Gram-negative pathogens collected from pediatric patients; A. baumannii and P. aeruginosa were susceptible to fewer antimicrobial agents. Susceptibility rates among isolates from pediatric patients were frequently different from those among isolates collected from adults.
Bacterial infections in pediatric patients may behave differently than their corresponding infections in adults. Lob et al. showed that Escherichia coli isolates from adults with appendicitis were significantly (P Ͻ 0.05) less susceptible to a number of antimicrobial agents than were those from pediatric patients (1). Pediatric patients have rates of bacteremia up to 2-fold higher than those for adult patients and 7-fold higher than those for neonates (2). Unfortunately, results for pediatric and adult patients are often grouped together in population-based study reports (3).Key factors in the spread of serious Gram-negative bacilli include the development and spread of numerous resistance mechanisms, decreased research into the development of new antimicrobial agents, and widespread overuse of broad-spectrum antimicrobial agents in the treatment of infections, among other factors (4). Gram-negative pathogens are commonly associated with serious infections and high morbidity and mortality rates. Infections caused by Gram-negative pathogens are common causes of death among patients less than 14 years of age in the United Kingdom (5), and ...